ResultsIQ

ResultsIQ › Latest results › Global Health Limited

Global Health Limited Q1 FY27 results press release summary

NSE: MEDANTA · BSE: 543654

Results press release of 30 Jul 2026, summarised by AI from the filing.

Medanta Q1 FY27 total income ₹13,262 million, up 26.2% y-o-y, with EBITDA ₹3,153 million, up 23.5% y-o-y.

Key takeaways

  1. Guidance New 80 bed cancer facility in Indore expected to be operationalised in the next few months.
  2. Noida turnaround Noida EBITDA loss narrowed to ₹49 million in Q1 FY27 from ₹236 million in Q4 FY26.
  3. Growth driver Significant growth in patient volumes and improved realisations drove the quarter's performance.
  4. Margin pressure EBITDA margins declined 51 bps y-o-y to 23.8% and PAT fell 1.1% y-o-y to ₹1,573 million.

Original filing on BSE

Global Health Limited Q1 FY27 results

As filed: Revenue ₹1,304 cr (+26% year on year), EBITDA ₹287 cr (+26% year on year), PAT ₹157 cr (−1% year on year), EBITDA margin 22.0% (−3 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹1,159 cr (+25% year on year), EBITDA ₹244 cr (+9% year on year), PAT ₹142 cr (+40% year on year), EBITDA margin 21.0% (−303 bps). Score 67 of 100, Above trend. Revenue and profit growth were well above the company's own trend; EBITDA growth was in line with it. EBITDA margin fell 303 bps year on year. Share price after the results: +1.9% in 29 days (Nifty 500: −0.1%).
  • Q3 FY26: Revenue ₹1,121 cr (+19% year on year), EBITDA ₹217 cr (−8% year on year), PAT ₹95.0 cr (−17% year on year), EBITDA margin 19.4% (−575 bps). Score 34 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA and profit before exceptional items growth were well below it. EBITDA margin fell 575 bps year on year. Profit fell 15% from last quarter. Revenue rose ₹178 cr on a year ago, more than the ₹110 cr it added the year before. Share price after the results: −1.1% in 30 days (Nifty 500: −4.5%).
  • Q2 FY26: Revenue ₹1,099 cr (+15% year on year), EBITDA ₹231 cr (+1% year on year), PAT ₹158 cr (+21% year on year), EBITDA margin 21.0% (−281 bps). Score 42 of 100, In line with trend. Revenue and profit growth were in line with the company's own trend; EBITDA growth was well below it. EBITDA margin fell 281 bps year on year. Revenue rose ₹142 cr on a year ago, more than the ₹113 cr it added the year before. Share price after the results: −7.1% in 28 days (Nifty 500: +1.3%).
  • Q1 FY26: Revenue ₹1,031 cr (+20% year on year), EBITDA ₹227 cr (+21% year on year), PAT ₹159 cr (+50% year on year), EBITDA margin 22.0% (+30 bps). Score 75 of 100, Above trend. Revenue and profit growth were well above the company's own trend; EBITDA growth was above it. EBITDA margin rose 30 bps year on year. Revenue rose ₹170 cr on a year ago, more than the ₹88.0 cr it added the year before. Share price after the results: +6.1% in 29 days (Nifty 500: +0.6%).
  • Q4 FY25: Revenue ₹931 cr (+15% year on year), EBITDA ₹224 cr (+25% year on year), PAT ₹101 cr (+28% year on year), EBITDA margin 24.1% (+193 bps). Score 67 of 100, Above trend. Revenue growth was in line with the company's own trend; EBITDA growth was well above it; profit before exceptional items growth was above it. EBITDA margin rose 193 bps year on year. Profit fell 3% from last quarter. Revenue rose ₹122 cr on a year ago, more than the ₹106 cr it added the year before. Share price after the results: −4.6% in 29 days (Nifty 500: +0.5%).
  • Q3 FY25: Revenue ₹943 cr (+13% year on year), EBITDA ₹237 cr (+12% year on year), PAT ₹143 cr (+15% year on year), EBITDA margin 25.1% (−32 bps). Score 44 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin fell 32 bps year on year.
  • Q2 FY25: Revenue ₹957 cr (+13% year on year), EBITDA ₹228 cr (+7% year on year), PAT ₹131 cr (+5% year on year), EBITDA margin 23.8% (−141 bps). Score 44 of 100, In line with trend. EBITDA margin fell 141 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Global Health Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.